<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33548">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02021019</url>
  </required_header>
  <id_info>
    <org_study_id>527/13</org_study_id>
    <secondary_id>1052470</secondary_id>
    <nct_id>NCT02021019</nct_id>
  </id_info>
  <brief_title>Renal Denervation to Improve Outcomes in Patients With End-stage Renal Disease</brief_title>
  <official_title>Renal Denervation to Improve Outcomes in Patients With End-stage Renal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker IDI Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker IDI Heart and Diabetes Institute</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sympathetic activation is a hallmark of end-stage renal disease and adversely affects
      cardiovascular prognosis. Hypertension is present in the vast majority of these patients and
      plays a key role in the progressive deterioration of renal function and in the exceedingly
      high rate of cardiovascular events. Selective catheter-based renal denervation has been
      shown to be safe and effective in attaining improved and sustained blood pressure control in
      patients with resistant hypertension and normal renal function. The investigators
      hypothesize that catheter-based renal denervation is a safe and effective intervention to
      achieve sustained reduction in sympathetic nerve activity, BP and target organ damage in
      hypertensive ESRD patients, which will result in improved cardiovascular outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Blood Pressure change</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Difference in the reduction of systolic office blood pressure between the renal denervation and control group at 6 months after the procedure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>End-stage Renal Disease</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation using a catheter-based RF approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal Denervation</intervention_name>
    <arm_group_label>Renal Denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  end stage renal disease

          -  hypertension (BPâ‰¥140/90mmHg)

        Exclusion Criteria:

          -  Individual has renal artery anatomy that is ineligible for treatment as assessed by
             the interventionalist.

          -  Individual has experienced a myocardial infarction, unstable angina, or a
             cerebrovascular accident within 3 months of the screening visit.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus P Schlaich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker IDI Heart and Diabetes Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus P Schlaich, MD</last_name>
    <phone>0061 3 8532 1502</phone>
    <email>markus.schlaich@bakeridi.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petra Marusic, BSc</last_name>
    <phone>0061 3 8532 1734</phone>
    <email>petra.marusic@bakeridi.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baker IDI Heart and Diabetes Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Markus P Schlaich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
